Showing results (1401-1410 of 1,485) with videos related to

Sort By:
Pageof 149
Journal of Cancer Survivorship : Research and Practice|November 2, 2011
How confident are young adult cancer survivors in managing their survivorship care? A report from the LIVESTRONG™ Survivorship Center of Excellence NetworkJacqueline Casillas, Karen L Syrjala, Patricia A Ganz, et al.
Alimentary Pharmacology & Therapeutics|February 19, 2025
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' PerspectiveZobair M Younossi, Homie Razavi, Michael Sherman, et al.
Radiation Research|December 7, 2010
Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor studyParveen Bhatti, Lene H S Veiga, Cécile M Ronckers, et al.
Oncogene|April 10, 2018
A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinomaIsmail Labgaa, Carlos Villacorta-Martin, Delia D'Avola, et al.
Journal of the American Society of Nephrology : JASN|November 10, 2012
Circulating suPAR in two cohorts of primary FSGSChangli Wei, Howard Trachtman, Jing Li, et al.
Science Translational Medicine|October 6, 2021
Targeting epigenetically maladapted vascular niche alleviates liver fibrosis in nonalcoholic steatohepatitisHua Zhang, Yongyuan Ma, Xinying Cheng, et al.
The Journal of Rheumatology|August 17, 2013
A randomized controlled trial of an internal family systems-based psychotherapeutic intervention on outcomes in rheumatoid arthritis: a proof-of-concept studyNancy A Shadick, Nancy F Sowell, Michelle L Frits, et al.
EMBO Molecular Medicine|November 8, 2017
SOX9 predicts progression toward cirrhosis in patients while its loss protects against liver fibrosisVarinder S Athwal, James Pritchett, Jessica Llewellyn, et al.
Hepatology (Baltimore, Md.)|June 22, 2021
Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular CarcinomaLaura Torrens, Carla Montironi, Marc Puigvehí, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 29, 2020
Hepatocyte KLF6 expression affects FXR signalling and the clinical course of primary sclerosing cholangitisSvenja Sydor, Paul Manka, Lea van Buren, et al.
Pageof 149